Is Dextropropoxyphene 60mg capsules a controlled drug in the UK?

Yes, Dextropropoxyphene 60mg capsules is classified as Schedule 5 (CD Inv) under the UK Misuse of Drugs Regulations. This means there are special legal requirements for prescribing, dispensing, and storing this medicine. (Source: NHS dm+d, UK Misuse of Drugs Regulations 2001)

What should I avoid while taking Dextropropoxyphene 60mg capsules?

Avoid alcohol. Take with or without food. Food does not significantly affect absorption. (Source: DrugBank, licensed under CC BY-NC 4.0)

Do I need a prescription for Dextropropoxyphene 60mg capsules?

Dextropropoxyphene 60mg capsules is classified as a Valid as a prescribable product in the UK. However, always consult a pharmacist or doctor before use. (Source: NHS dm+d)

What are the brand names for Dextropropoxyphene 60mg capsules?

Dextropropoxyphene 60mg capsules is the generic name. It is available under brand names including: Doloxene 100mg capsules. (Source: NHS dm+d — Actual Medicinal Products)

Dextropropoxyphene 60mg capsules

Capsule

60mg

Oral

Dextropropoxyphene is an opioid analgesic manufactured by Eli Lilly and Company.

Active ingredients:

Dextropropoxyphene

CD Schedule 5

Lowest controls; includes some codeine preparations

details

BNF classificationBrowse formulary

Where this medicine sits in the British National Formulary — the UK's standard prescribing reference

BNF 04.07.02

ATC classificationBrowse ATC index

International classification by the WHO, grouping medicines by the organ system they act on

ATC N02AC04

Chemical classBrowse classes

Classification based on the molecule's chemical structure and properties

Check interactions for Dextropropoxyphene

1 safety notice

Schedule 5

Legal requirements and restrictions

Preparations containing controlled drugs in low concentrations. Subject to minimal controls - mainly invoicing requirements.

Legal requirements

No special prescription requirements
No controlled drugs register required
No safe custody requirements
Invoices must be retained for 2 years

Other medicines in this category

Codeine linctus, Co-codamol (low strength), Kaolin and morphine

View full UK controlled drugs list

Official documents, adverse reaction reporting, and safety monitoring

Report a side effect

Submit a Yellow Card report to the MHRA

Safety monitoring data

Yellow Card reports

MHRA

The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.

View Drug Analysis Profile

Suspected adverse reactions reported for Dextropropoxyphene

Browse all iDAP reports

Interactive Drug Analysis Profiles for all medicines

Report a side effect

Submit a Yellow Card report to the MHRA

Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.

EudraVigilance

EMA

The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.

View EudraVigilance report

Suspected adverse reactions reported for Dextropropoxyphene

About EudraVigilance

Learn about EU pharmacovigilance and safety monitoring

EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.

1 branded products available

1 productsShow details

1 products

Possibly available on the UK marketDiscontinuedAvailability per NHS dm+d

MHRA licensed products

View all licensed products for Dextropropoxyphene on the MHRA register

Doloxene 100mg capsules

Eli Lilly and Company Ltd

Discontinued

Source: NHS dm+dOGL 3.0

Updated about 1 month ago(1 Mar 2026)

Daily doseShow details

WHO defined daily dose (DDD)

300 mg

Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.

Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via NHS dm+d BNF mapping files. Contains public sector information licensed under the Open Government Licence v3.0.

Therapeutically similar medicines

10 similarShow details

Dextromoramide 10mg tablets

Tablet

10mg

Same therapeutic group

Dextromoramide 5mg tablets

Tablet

5mg

Same therapeutic group

Celecoxib 120mg/4.8ml oral solution unit dose bottles sugar free

Oral solution

120mg/4.8ml

Same BNF section

Clonidine 100micrograms/5ml oral solution sugar free

Oral solution

5ml

Same BNF section

Tapentadol 100mg tablets

Tablet

100mg

Same BNF section

Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.

NHS prescribing volume and spending trends

Show details

Loading prescribing data...

Clinical guidelines and formulary information

British National Formulary

Dextropropoxyphene

BNF

Drug monograph — bnf.nice.org.uk

Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.

Check stock at pharmacies and supply information

Show details

Pharmacy stock checkers

Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.

Boots

Search products

Click & collectNHS

Lloyds

Search products

DeliveryNHS

P2U

Pharmacy2U

Search products

DeliveryNHS

Supply & product information

Official product databases and supply status monitoring

Shortages info

NHS Specialist Pharmacy Service (SPS)

emc product search

Discontinuations & alternatives for Dextropropoxyphene

Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.

Codes for healthcare professionals and prescribing systems

Show details

These codes are used by healthcare IT systems and prescribers to identify this medicine.

NHS UK identifiers

SNOMED CT

42011111000001106

dm+d ID

42011111000001106

VTM (Virtual Therapeutic Moiety)

775536007

VMP (Virtual Medicinal Product)

42011111000001106

BNF code

04070200

International identifiers

ATC code — Anatomical Therapeutic Chemical (WHO)

N02AC04

Browse tools

dm+d Browser

NHSBSA medicines dictionary lookup

SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).

Active and completed clinical studies from ClinicalTrials.gov

Show details

Searching UK clinical trials...

Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.

Pharmacology and chemical data from DrugBank

go.drugbank.com

Key facts

Drug status

Approved

Major interactions

51 found

Half-life

6-12 hours

Mechanism

Propoxyphene acts as a weak agonist at OP1, OP2, and OP3 opiate receptors within the central nervous system (CNS).

Food interactions

2 warnings

Human targets

4 targets

Data: DrugBank · CC BY-NC 4.0

Pharmacokinetics at a glance

Half-life

6-12 hours

6-12 hours

Volume of distribution

16 L/kg

* 16 L/kg

Metabolism

Hepatic

Elimination

48 hours

The major route of metabolism is cytochrome CYP3A4 mediated N-demethylation to norpropoxyphene, which is excreted by the kidneys.…

Clearance

2.6 L

* 2.6 L/min

Pharmacokinetic data: DrugBank · CC BY-NC 4.0

Status:

Approved

Illicit

Withdrawn

Small molecule

About this compound

Dextropropoxyphene is an opioid analgesic manufactured by Eli Lilly and Company. It is used in the symptomatic treatment of mild pain. It displays antitussive and local anaesthetic actions. Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the market in Europe and the United States. The drug is often referred to as the general form, "propoxyphene", however only the dextro-isomer (dextropropoxyphene) has any analgesic effect. The levo-isomer appears to exhibit a very limited antitussive effect.

Properties:

solid

Avg. mass: 339.47 Da

DrugBank indication

For the relief of mild to moderate pain.

Also known as(134)

d-Propoxyphene

Destropropossifene

Dextropropoxifeno

Dextropropoxyphen

Dextropropoxyphène

Dextropropoxyphene

Dextropropoxyphenum

Dextroproxifeno

Dosage forms(12)

Tablet (Oral) — 65 mg

Capsule (Oral)

Capsule (Oral) — 100 mg

Tablet, film coated (Oral) — 100 mg/1

Pill (Oral) — 30 MG

Suppository — 30 MG

Suppository — 75 MG

Capsule (Oral) — 65 mg

Molecular properties(18)

Drug interactions(1281)

Known interactions with other medications. Always consult a healthcare professional.

Buprenorphine

Moderate

DB00921

Dextropropoxyphene may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.

Check this interaction

Doxylamine

Moderate

DB00366

Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Dextropropoxyphene.

Check this interaction

Dronabinol

Unknown severity

DB00470

The serum concentration of Dronabinol can be increased when it is combined with Dextropropoxyphene.

Check this interaction

Droperidol

Moderate

DB00450

Droperidol may increase the central nervous system depressant (CNS depressant) activities of Dextropropoxyphene.

Check this interaction

Hydrocodone

Moderate

DB00956

Dextropropoxyphene may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.

Check this interaction

Hydroxyzine

Moderate

DB00557

Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Dextropropoxyphene.

Check this interaction

Magnesium sulfate

Moderate

DB00653

The therapeutic efficacy of Dextropropoxyphene can be increased when used in combination with Magnesium sulfate.

Check this interaction

Methotrimeprazine

Moderate

DB01403

Dextropropoxyphene may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.

Check this interaction

Metyrosine

Moderate

DB00765

Dextropropoxyphene may increase the sedative activities of Metyrosine.

Check this interaction

Minocycline

Moderate

DB01017

Minocycline may increase the central nervous system depressant (CNS depressant) activities of Dextropropoxyphene.

Check this interaction

Nabilone

Moderate

DB00486

Nabilone may increase the central nervous system depressant (CNS depressant) activities of Dextropropoxyphene.

Check this interaction

Orphenadrine

Moderate

DB01173

Dextropropoxyphene may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.

Check this interaction

Paraldehyde

Moderate

DB09117

Dextropropoxyphene may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.

Check this interaction

Perampanel

Moderate

DB08883

Perampanel may increase the central nervous system depressant (CNS depressant) activities of Dextropropoxyphene.

Check this interaction

Pramipexole

Moderate

DB00413

Dextropropoxyphene may increase the sedative activities of Pramipexole.

Check this interaction

Ropinirole

Moderate

DB00268

Dextropropoxyphene may increase the sedative activities of Ropinirole.

Check this interaction

Rotigotine

Moderate

DB05271

Dextropropoxyphene may increase the sedative activities of Rotigotine.

Check this interaction

Rufinamide

Unknown severity

DB06201

The risk or severity of adverse effects can be increased when Rufinamide is combined with Dextropropoxyphene.

Check this interaction

Sodium oxybate

Moderate

DB09072

Dextropropoxyphene may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.

Check this interaction

Suvorexant

Moderate

DB09034

Dextropropoxyphene may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.

Check this interaction

Tapentadol

Moderate

DB06204

Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Dextropropoxyphene.

Check this interaction

Thalidomide

Moderate

DB01041

Dextropropoxyphene may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.

Check this interaction

Zolpidem

Moderate

DB00425

Dextropropoxyphene may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.

Check this interaction

Alvimopan

Unknown severity

DB06274

The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Alvimopan.

Check this interaction

Desmopressin

Unknown severity

DB00035

The risk or severity of hyponatremia can be increased when Dextropropoxyphene is combined with Desmopressin.

Check this interaction

Morphine

Unknown severity

DB00295

The risk or severity of adverse effects can be increased when Morphine is combined with Dextropropoxyphene.

Check this interaction

Codeine

Unknown severity

DB00318

The risk or severity of adverse effects can be increased when Codeine is combined with Dextropropoxyphene.

Check this interaction

Hydromorphone

Unknown severity

DB00327

The risk or severity of adverse effects can be increased when Hydromorphone is combined with Dextropropoxyphene.

Check this interaction

Oxycodone

Unknown severity

DB00497

The risk or severity of adverse effects can be increased when Oxycodone is combined with Dextropropoxyphene.

Check this interaction

Naltrexone

Moderate

DB00704

The therapeutic efficacy of Dextropropoxyphene can be decreased when used in combination with Naltrexone.

Check this interaction

Sufentanil

Unknown severity

DB00708

The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Sufentanil.

Check this interaction

Levorphanol

Unknown severity

DB00854

The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Levorphanol.

Check this interaction

Remifentanil

Unknown severity

DB00899

The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Remifentanil.

Check this interaction

Diphenoxylate

Unknown severity

DB01081

The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Diphenoxylate.

Check this interaction

Oxymorphone

Unknown severity

DB01192

The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Oxymorphone.

Check this interaction

Dezocine

Unknown severity

DB01209

The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Dezocine.

Check this interaction

Methadyl acetate

Unknown severity

DB01433

The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Methadyl acetate.

Check this interaction

Dihydroetorphine

Unknown severity

DB01450

The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Dihydroetorphine.

Check this interaction

Diamorphine

Unknown severity

DB01452

The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Diamorphine.

Check this interaction

Bezitramide

Unknown severity

DB01459

The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Bezitramide.

Check this interaction

Ethylmorphine

Unknown severity

DB01466

The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Ethylmorphine.

Check this interaction

Etorphine

Unknown severity

DB01497

The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Etorphine.

Check this interaction

Dextromoramide

Unknown severity

DB01529

The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Dextromoramide.

Check this interaction

Desomorphine

Unknown severity

DB01531

The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Desomorphine.

Check this interaction

Carfentanil

Unknown severity

DB01535

The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Carfentanil.

Check this interaction

Dihydrocodeine

Unknown severity

DB01551

The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Dihydrocodeine.

Check this interaction

Alphacetylmethadol

Unknown severity

DB01555

The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Alphacetylmethadol.

Check this interaction

Dihydromorphine

Unknown severity

DB01565

The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Dihydromorphine.

Check this interaction

Ketobemidone

Unknown severity

DB06738

The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Ketobemidone.

Check this interaction

DPDPE

Unknown severity

DB08861

The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with DPDPE.

Check this interaction

Showing 50 of 1281 interactions

Food & lifestyle interactions

Avoid Alcohol

Avoid alcohol.

Advice

Take with or without food. Food does not significantly affect absorption.

Toxicity & overdose

Coma, respiratory depression, circulatory collapse, and pulmonary edema. Seizures occur more frequently in patients with propoxyphene intoxication than in those with opiate intoxication. LD₅₀=230mg/kg (orally in rat, Emerson)

How it works

Mechanism of action

Propoxyphene acts as a weak agonist at OP1, OP2, and OP3 opiate receptors within the central nervous system (CNS). Propoxyphene primarily affects OP3 receptors, which are coupled with G-protein receptors and function as modulators, both positive and negative, of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine, and noradrenaline is inhibited. Opioids such as propoxyphene also inhibit the release of vasopressin, somatostatin, insulin, and glucagon. Opioids close N-type voltage-operated calcium channels (OP2-receptor agonist) and open calcium-dependent inwardly rectifying potassium channels (OP3 and OP1 receptor agonist). This results in hyperpolarization and reduced neuronal excitability.

Pharmacodynamics

Propoxyphene, a synthetic opiate agonist, is structurally similar to methadone. Its general pharmacologic properties are those of the opiates as a group. The analgesic effect of propoxyphene is due to the d-isomer, dextropropoxyphene. It binds to the opiate receptors and leads to a decrease of the perception of pain stimuli. Propoxyphene possesses little to no antitussive activity and no antipyretic action.

Pharmacokinetics

How the body processes this drug — absorption, distribution, metabolism, and elimination

Half-life

6-12 hours

Volume of distribution

* 16 L/kg

Metabolism

Hepatic

Route of elimination

The major route of metabolism is cytochrome CYP3A4 mediated N-demethylation to norpropoxyphene, which is excreted by the kidneys.
In 48 hours, approximately 20% to 25% of the administered dose of propoxyphene is excreted via the urine, most of which is free or conjugated norpropoxyphene.

Clearance

* 2.6 L/min

Drug targets(4)

Proteins and enzymes this drug interacts with in the body

Mu-type opioid receptor

BE0000770

OPRM1

agonist

Specific functionbeta-endorphin receptor activity

Cellular location

Cell membrane

General function & pharmacology

Receptor for endogenous opioids such as beta-endorphin and endomorphin .
PMID:10529478 PMID:12589820 PMID:7891175 PMID:7905839 PMID:7957926 PMID:9689128

Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone .
PMID:10529478 PMID:10836142 PMID:12589820 PMID:19300905 PMID:7891175 PMID:7905839 PMID:7957926 PMID:9689128

Also activated by enkephalin peptides, such as Met-enkephalin or Met-enkephalin-Arg-Phe, with higher affinity for Met-enkephalin-Arg-Phe (By similarity). Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociation of the G-protein complex with the free GTP-bound G-protein alpha and the G-protein beta-gamma dimer activating downstream cellular effectors .
PMID:7905839
The agonist- and cell type-specific activity is predominantly coupled to pertussis toxin-sensitive G(i) and G(o) G alpha proteins, GNAI1, GNAI2, GNAI3 and GNAO1 isoforms Alpha-1 and Alpha-2, and to a lesser extent to pertussis toxin-insensitive G alpha proteins GNAZ and GNA15 .
PMID:12068084
They mediate an array of downstream cellular responses, including inhibition of adenylate cyclase activity and both N-type and L-type calcium channels, activation of inward rectifying potassium channels, mitogen-activated protein kinase (MAPK), phospholipase C (PLC), phosphoinositide/protein kinase (PKC), phosphoinositide 3-kinase (PI3K) and regulation of NF-kappa-B (By similarity). Also couples to adenylate cyclase stimulatory G alpha proteins (By similarity).

The selective temporal coupling to G-proteins and subsequent signaling can be regulated by RGSZ proteins, such as RGS9, RGS17 and RGS4 (By similarity). Phosphorylation by members of the GPRK subfamily of Ser/Thr protein kinases and association with beta-arrestins is involved in short-term receptor desensitization (By similarity). Beta-arrestins associate with the GPRK-phosphorylated receptor and uncouple it from the G-protein thus terminating signal transduction (By similarity).

The phosphorylated receptor is internalized through endocytosis via clathrin-coated pits which involves beta-arrestins (By similarity). The activation of the ERK pathway occurs either in a G-protein-dependent or a beta-arrestin-dependent manner and is regulated by agonist-specific receptor phosphorylation (By similarity). Acts as a class A G-protein coupled receptor (GPCR) which dissociates from beta-arrestin at or near the plasma membrane and undergoes rapid recycling (By similarity).

Receptor down-regulation pathways are varying with the agonist and occur dependent or independent of G-protein coupling (By similarity). Endogenous ligands induce rapid desensitization, endocytosis and recycling (By similarity). Heterooligomerization with other GPCRs can modulate agonist binding, signaling and trafficking properties (By similarity)

Delta-type opioid receptor

BE0000420

OPRD1

agonist

Specific functionG protein-coupled enkephalin receptor activity

Cellular location

Cell membrane

General function & pharmacology

G-protein coupled receptor that functions as a receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity.

Inhibits neurotransmitter release by reducing calcium ion currents and increasing potassium ion conductance. Plays a role in the perception of pain and in opiate-mediated analgesia. Plays a role in developing analgesic tolerance to morphine

Kappa-type opioid receptor

BE0000632

OPRK1

antagonist

Specific functiondynorphin receptor activity

Cellular location

Cell membrane

General function & pharmacology

G-protein coupled opioid receptor that functions as a receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as a receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase.

Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurotransmitter release by reducing calcium ion currents and increasing potassium ion conductance. Plays a role in the perception of pain.

Plays a role in mediating reduced physical activity upon treatment with synthetic opioids. Plays a role in the regulation of salivation in response to synthetic opioids. May play a role in arousal and regulation of autonomic and neuroendocrine functions

Glutamate receptor ionotropic, NMDA 3B

BE0004956

GRIN3B

antagonist

Specific functioncalcium channel activity

Cellular location

Cell membrane

General function & pharmacology

Component of a non-conventional N-methyl-D-aspartate (NMDA) receptors (NMDARs) that function as heterotetrameric, ligand-gated cation channels with low calcium permeability and low voltage-dependent block by Mg(2+) (By similarity). Forms glutamatergic receptor complexes with GluN1 and GluN2 subunits which are activated by glycine binding to the GluN1 and GluN3 subunits and L-glutamate binding to GluN2 subunits (By similarity). Forms excitatory glycinergic receptor complexes with GluN1 alone which are activated by glycine binding to the GluN1 and GluN3 subunits.

GluN3B subunit also binds D-serine and, in the absence of glycine, activates glycinergic receptor complexes, but with lower efficacy than glycine (By similarity). Each GluN3 subunit confers differential attributes to channel properties, including activation, deactivation and desensitization kinetics, pH sensitivity, Ca2(+) permeability, and binding to allosteric modulators (By similarity)

Metabolizing enzymes(5)

Enzymes involved in drug metabolism — important for understanding drug interactions

Enzyme activity key

substrate

inhibitor

inducer

CYP2D6Cytochrome P450 2D6

substrate

inhibitor

CYP3A4Cytochrome P450 3A4

substrate

inhibitor

CYP3A7Cytochrome P450 3A7 · Cytochrome P450 3A Subfamily

inhibitor

UGT2B4UDP-glucuronosyltransferase 2B4

inhibitor

CES1Liver carboxylesterase 1

substrate

Biological pathways(1)

Propoxyphene Action Pathway

Involved compounds

ATP,Calcium,Dextropropoxyphene,Dopamine,Norepinephrine,Potassium cation

Scientific references(3)

Coda B.A., Rudy A.C., Archer S.M., Wermeling D.P.

Pharmacokinetics and Bioavailability of Single-Dose Intranasal Hydromorphone Hydrochloride in Healthy Volunteers. Anesthesia & Analgesia. 2003;:117-123. doi: 10.1213/01.ane.0000066311.

40978

PMID: 12818953 DOI: 10.1213/01.ane.0000066311.40978.4f

Ulens C., Daenens P., Tytgat J.

Norpropoxyphene-induced cardiotoxicity is associated with changes in ion-selectivity and gating of HERG currents.

Cardiovascular Research

199944(3):568-578. doi: 10.1016/s0008-6363(99)00258-8

PMID: 10690289 DOI: 10.1016/s0008-6363(99)00258-8

Tyers M.B.

A CLASSIFICATION OF OPIATE RECEPTORS THAT MEDIATE ANTINOCICEPTION IN ANIMALS.

British Journal of Pharmacology

198069(3):503-512. doi: 10.1111/j.1476-5381.1980.tb07041.x

PMID: 6249436 DOI: 10.1111/j.1476-5381.1980.tb07041.x

ATC classification(3 codes)

ATC N02AC04

ATC N02AC54

ATC N02AC74

Affected organisms(1)

Humans and other mammals

International brands(6)

Salt forms(2)

Dextropropoxyphene hydrochloride(DBSALT000500)

Dextropropoxyphene napsylate(DBSALT001000)

Experimental properties(3)

External resources(2)

RxList Drugs.com

Commercial products(72)

Chemical identifiers

CAS, UNII, InChI Key and database cross-references

Show

Linked compound data from DrugBank Open Data (CC BY-NC 4.0)

Dextropropoxyphene

DB00647

CAS number

469-62-5

UNII (FDA)

S2F83W92TK

InChI Key (molecular fingerprint)

XLMALTXPSGQGBX-GCJKJVERSA-N

Additional database identifiers

Drugs Product Database (DPD)

9952

Drugs Product Database (DPD)

2555

ChEBI

51173

PubChem Compound

10100

PubChem Substance

46506690

KEGG Compound

C07406

KEGG Drug

D07809

ChemSpider

9696

BindingDB

82269

PharmGKB

PA451142

Therapeutic Targets Database

DAP000017

Wikipedia

Dextropropoxyphene

ChEMBL

CHEMBL1213351

ZINC

ZINC000001530769

RxCUI

8785

HUGO Gene Nomenclature Committee (HGNC)

HGNC:8156

GenAtlas

OPRM1

GeneCards

OPRM1

GenBank Gene Database

L25119

GenBank Protein Database

452073

IUPHAR

319

Guide to Pharmacology

319

UniProtKB

P35372

UniProt Accession

OPRM_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:8153

GenAtlas

OPRD1

GeneCards

OPRD1

GenBank Gene Database

U07882

GenBank Protein Database

27545517

IUPHAR

317

Guide to Pharmacology

317

UniProtKB

P41143

UniProt Accession

OPRD_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:8154

GenAtlas

OPRK1

GeneCards

OPRK1

GenBank Gene Database

U11053

GenBank Protein Database

532060

IUPHAR

318

Guide to Pharmacology

318

UniProtKB

P41145

UniProt Accession

OPRK_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4584

GenAtlas

GRIN1

GeneCards

GRIN1

GenBank Gene Database

D13515

GenBank Protein Database

219920

IUPHAR

455

Guide to Pharmacology

455

UniProtKB

Q05586

UniProt Accession

NMDZ1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4585

GenAtlas

GRIN2A

GeneCards

GRIN2A

GenBank Gene Database

U09002

GenBank Protein Database

558749

IUPHAR

456

Guide to Pharmacology

456

UniProtKB

Q12879

UniProt Accession

NMDE1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4586

GenAtlas

GRIN2B

GeneCards

GRIN2B

GenBank Gene Database

U90278

GenBank Protein Database

1899202

IUPHAR

457

Guide to Pharmacology

457

UniProtKB

Q13224

UniProt Accession

NMDE2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4587

GenAtlas

GRIN2C

GeneCards

GRIN2C

GenBank Gene Database

L76224

GenBank Protein Database

1196449

IUPHAR

458

Guide to Pharmacology

458

UniProtKB

Q14957

UniProt Accession

NMDE3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4588

GenAtlas

GRIN2D

GeneCards

GRIN2D

GenBank Gene Database

U77783

GenBank Protein Database

2444026

IUPHAR

459

UniProtKB

O15399

UniProt Accession

NMDE4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:16767

GenAtlas

GRIN3A

GeneCards

GRIN3A

GenBank Gene Database

AJ416950

GenBank Protein Database

20372905

IUPHAR

460

UniProtKB

Q8TCU5

UniProt Accession

NMD3A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:16768

GenAtlas

GRIN3B

GeneCards

GRIN3B

GenBank Gene Database

AC004528

GenBank Protein Database

3025446

IUPHAR

461

UniProtKB

O60391

UniProt Accession

NMD3B_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2625

GenAtlas

CYP2D6

GeneCards

CYP2D6

GenBank Gene Database

M20403

GenBank Protein Database

181350

Guide to Pharmacology

1329

UniProtKB

P10635

UniProt Accession

CP2D6_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2637

GenAtlas

CYP3A4

GeneCards

CYP3A4

GenBank Gene Database

M18907

Guide to Pharmacology

1337

UniProtKB

P08684

UniProt Accession

CP3A4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2637

GenAtlas

CYP3A4

GeneCards

CYP3A4

GenBank Gene Database

M18907

Guide to Pharmacology

1337

UniProtKB

P08684

UniProt Accession

CP3A4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:17450

GeneCards

CYP3A43

GenBank Gene Database

AF319634

GenBank Protein Database

12642642

UniProtKB

Q9HB55

UniProt Accession

CP343_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2638

GenAtlas

CYP3A5

GeneCards

CYP3A5

GenBank Gene Database

J04813

GenBank Protein Database

181346

Guide to Pharmacology

1338

UniProtKB

P20815

UniProt Accession

CP3A5_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2640

GeneCards

CYP3A7

GenBank Gene Database

D00408

GenBank Protein Database

220149

UniProtKB

P24462

UniProt Accession

CP3A7_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:12553

GeneCards

UGT2B4

GenBank Gene Database

Y00317

GenBank Protein Database

37589

UniProtKB

P06133

UniProt Accession

UD2B4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1863

GenAtlas

CES1

GeneCards

CES1

GenBank Gene Database

M73499

Guide to Pharmacology

2592

UniProtKB

P23141

UniProt Accession

EST1_HUMAN

International reference pricing

9 formulations

Reference pricing from DrugBank. Prices are indicative and may not reflect current UK costs.

From $0.43/capsule

To $5.33/g

Propoxyphene hcl 65 mg capsule

$0.43/capsule

Propoxyphene N-APAP 100-650 mg tablet

$0.47/tablet

Propoxyphene-APAP 65-650 mg tablet

$0.57/tablet

Propoxyphene N-APAP 50-325 mg tablet

$1.32/tablet

Darvon 65 mg pulvule

$1.49/each

Source: DrugBank. Used under CC BY-NC 4.0 academic licence for non-commercial purposes.

DrugBank citations

If you use DrugBank data in your research, please cite the following publications:

Knox C., Wilson M., Klinger C.M., et al

DrugBank 6.

0: the DrugBank Knowledgebase for 2024

Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275

PMID: 37953279

Wishart D.S., Feunang Y.D., Guo A.C., et al

DrugBank 5.

0: a major update to the DrugBank database for 2018

Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082

PMID: 29126136

Show earlier publications

Law V., Knox C., Djoumbou Y., et al

DrugBank 4.

0: shedding new light on drug metabolism

Nucleic Acids Res. 2014 Jan 142(1):D1091-7

PMID: 24203711

Knox C., Law V., Jewison T., et al

DrugBank 3.

0: a comprehensive resource for 'omics' research on drugs

Nucleic Acids Res. 2011 Jan39(Database issue):D1035-41

PMID: 21059682

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a knowledgebase for drugs, drug actions and drug targets.

Nucleic Acids Research

2008 Jan36(Database issue):D901-6

PMID: 18048412

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a comprehensive resource for in silico drug discovery and exploration.

Nucleic Acids Research

2006 Jan 134(Database issue):D668-72

PMID: 16381955

Source: go.drugbank.comCC BY-NC 4.0

Updated 27 days ago(8 Mar 2026)

Back to medicines

Dextropropoxyphene 60mg capsules

Legal requirements

Other medicines in this category

Safety monitoring data

Yellow Card reports

EudraVigilance

WHO defined daily dose (DDD)

British National Formulary

Pharmacy stock checkers

Supply & product information

NHS UK identifiers

International identifiers

Browse tools

Key facts

Pharmacokinetics at a glance

Half-life

Volume of distribution

Metabolism

Elimination

Clearance

Clinical essentials

Pharmacology

Deep science
10

Chemical identifiers

Dextropropoxyphene

Additional database identifiers

International reference pricing

DrugBank citations

Dextropropoxyphene 60mg capsules

Controlled drug information

Legal requirements

Other medicines in this category

Safety & regulatory

Safety monitoring data

Yellow Card reports

EudraVigilance

Brand versions and licensed products

NHS reimbursement price

WHO defined daily dose (DDD)

Medicines like this

Prescribing statistics

Guidance (NICE / BNF)

British National Formulary

Availability, stocks & shortages

Pharmacy stock checkers

Supply & product information

Professional identifiers

NHS UK identifiers

International identifiers

Browse tools

Clinical trials

DrugBank data

Key facts

Pharmacokinetics at a glance

Half-life

Volume of distribution

Metabolism

Elimination

Clearance

Clinical essentials

Pharmacology

Deep science10

Chemical identifiers

Dextropropoxyphene

Additional database identifiers

International reference pricing

DrugBank citations

Deep science
10